Loading…
TAVEXIA LIFECARE (BSE 539519)₹1.160.00%Distributors
In the Jun 2026 quarter (consolidated), TAVEXIA LIFECARE reported sales of ₹0.65 Cr, down 47.2% from Jun 2025, and net profit of −₹0.17 Cr, down 125.8% year on year. For the year to Mar 2026, sales were ₹32.35 Cr and net profit ₹0.22 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.47 | 1.53 | 0.80 | 0.71 | 1.57 | 1.97 | 1.06 | 1.23 | 16.91 | 5.72 | 8.53 | 0.65 |
| Expenses | 0.04 | 0.94 | 0.34 | 0.22 | 0.65 | 0.91 | 0.28 | 0.45 | 15.72 | 6.24 | 15.07 | 0.89 |
| Operating Profit | 0.44 | 0.60 | 0.47 | 0.50 | 0.93 | 1.07 | 0.79 | 0.79 | 1.17 | −0.55 | −6.55 | −0.25 |
| OPM % | 93.5% | 38.9% | 58.3% | 70.1% | 59.0% | 54.2% | 74.4% | 64.0% | 6.9% | −9.4% | −76.7% | −37.5% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.09 | 0.03 | 0.00 | 0.25 | 0.00 | 0.03 | 0.00 | 5.84 | 0.11 |
| Interest | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.04 |
| Depreciation | 0.10 | 0.09 | 0.19 | 0.11 | 0.11 | 0.10 | 0.13 | 0.09 | 0.14 | 0.17 | 0.19 | 0.15 |
| Profit before tax | 0.33 | 0.52 | 0.29 | 0.49 | 0.86 | 0.97 | 0.92 | 0.68 | 1.07 | −0.72 | −0.88 | −0.32 |
| Tax % | 20.6% | 25.5% | 75.1% | 27.1% | 27.1% | 27.2% | 7.7% | 5.8% | 25.5% | −1.4% | −18.3% | −48.3% |
| Net Profit | 0.28 | 0.39 | 0.07 | 0.35 | 0.63 | 0.70 | 0.85 | 0.66 | 0.79 | −0.71 | −0.72 | −0.17 |
| EPS (Rs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.44 | 1.30 | 1.55 | 2.22 | 3.57 | 5.28 | 32.35 | 31.81 |
| Expenses | 0.37 | 0.64 | 1.45 | 1.15 | 1.59 | 1.98 | 37.48 | 37.92 |
| Operating Profit | 0.08 | 0.67 | 0.11 | 1.08 | 1.98 | 3.30 | −5.15 | −6.18 |
| OPM % | 16.3% | 51.2% | 6.5% | 48.5% | 55.5% | 62.6% | −15.8% | −19.4% |
| Other Income | 0.00 | 0.00 | 0.00 | −0.05 | −0.02 | 0.36 | 5.88 | 5.98 |
| Interest | 0.07 | 0.04 | 0.01 | 0.04 | 0.01 | 0.04 | 0.03 | 0.06 |
| Depreciation | 0.02 | 0.03 | 0.07 | 0.23 | 0.39 | 0.43 | 0.56 | 0.65 |
| Profit before tax | 0.00 | 0.58 | 0.03 | 0.75 | 1.55 | 3.20 | 0.18 | −0.85 |
| Tax % | — | 25.5% | 0.0% | 27.7% | 22.1% | 22.0% | −23.5% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 0.00 | 0.45 | 0.03 | 0.56 | 1.20 | 2.50 | 0.22 | −0.81 |
| EPS (Rs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.01 |
| Dividend payout % | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 3.21 | 3.21 | 8.06 | 12.06 | 19.28 | 38.38 |
| Reserves | 0.45 | 0.52 | 7.45 | 10.17 | 4.72 | 4.88 |
| Borrowings | 0.09 | 0.09 | 0.23 | 0.16 | 0.51 | 3.49 |
| Other Liabilities | 0.51 | 0.64 | 0.63 | 0.91 | 2.16 | 64.80 |
| Total Liabilities | 4.26 | 4.46 | 16.37 | 23.30 | 26.67 | 112 |
| Fixed Assets | 0.00 | 0.14 | 1.50 | 1.12 | 1.14 | 3.78 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.04 | 8.14 | 10.91 | 10.92 | 12.77 |
| Other Assets | 4.26 | 4.28 | 6.73 | 11.27 | 14.61 | 95.00 |
| Inventories | 1.01 | 1.01 | 2.01 | 3.01 | 6.02 | 8.02 |
| Trade receivables | 1.01 | 2.01 | 3.01 | 5.01 | 6.02 | 11.04 |
| Cash & equivalents | 2.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 |
| Total Assets | 4.26 | 4.46 | 16.37 | 23.30 | 26.67 | 112 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | −0.60 | −0.93 | −1.48 | −2.78 | 0.12 | −14.35 |
| Cash from investing activity | −0.07 | 0.72 | −9.65 | −2.76 | −0.47 | −3.60 |
| Cash from financing activity | 0.88 | 0.04 | 11.19 | 5.53 | 0.38 | 19.37 |
| Net cash flow | 0.19 | −0.15 | 0.00 | −0.02 | 0.00 | 1.36 |
| Capex | 0.09 | 0.23 | 1.59 | 0.00 | 0.49 | 3.20 |
| Free cash flow | −0.66 | −1.15 | −3.06 | −2.78 | −0.36 | −17.54 |
| CFO / OP % | −88.9% | −919.9% | −117.9% | −123.0% | 25.1% | 281.1% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 385 | 457 | 499 | 512 | 385 | 125 |
| Inventory days | 1,460 | 543 | 2,579 | 1,035 | 2,404 | 81 |
| Days payable | 539 | 173 | 412 | 181 | 529 | 581 |
| Cash conversion cycle | 1,305 | 826 | 2,664 | 1,365 | 2,259 | −376 |
| Working capital days | 449 | 821 | 959 | 1,038 | 842 | 284 |
| ROCE % | — | 1.1% | 8.7% | 8.3% | 13.7% | 0.6% |
For the Jun 2026 quarter, TAVEXIA LIFECARE reported sales of ₹0.65 Cr, down 47.2% year on year and net profit of −₹0.17 Cr, down 125.8% year on year. The operating margin was −37.5%.
TAVEXIA LIFECARE's sales for the year to Mar 2026 were ₹32.35 Cr; over the last twelve months they were ₹31.81 Cr.
Net profit for the year to Mar 2026 was ₹0.22 Cr, and −₹0.81 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.01.
TAVEXIA LIFECARE reported borrowings of ₹3.49 Cr at Mar 2026, against cash and equivalents of ₹1.01 Cr.
Cash from operations was −₹14.35 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹17.54 Cr.